$SRNE So now Sorrento owns this drug... Dec 17 2020 Completion date. Fighti9ng Cancer and Covid - Yep! Metastatic Non-small Cell Lung Cancer Drug: AC0010 Detailed Description: The study is a single-arm, multi-center, open-label clinical trial. subjects' duration of response (DOR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS) and quality of life (QoL). Safety indicators of subjects are further evaluated through adverse events, vital signs and clinical laboratory parameters. Study Type : Interventional (Clinical Trial) Estimated Enrollment : 222 participants Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: the Treatment of EGFR T790M Mutation-positive Patients With Advanded NSCLC Actual Study Start Date : May 18, 2017 Estimated Primary Completion Date : June 17, 2019 Estimated Study Completion Date : December 17, 2020
  • 3
  • 1